Cardiol Therapeutics Inc. (Class A) (CRDL) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CRDL carries an RQD Score of 52 with a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:

• Fundamental Cash Engine: 12 / 20 (ROIC 0%; FCF yield 0%). Per the market data, the company reports zero return on invested capital and zero free-cash-flow yield, meaning the cash-engine pillar is weak and no internally generated cash return is evidenced in the source data.
• Whale 13F Flow: 8 / 20 (institutional accumulation and options positioning). This is the second-lowest pillar, indicating limited evidence of institutional conviction in the sources provided.
• Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider signal is weak in the scoring.
• Macro Regime Fit: 10 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 implies market-level sensitivity; the score reflects limited regime-fit support.
• Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, though still below midpoint, and the metrics suggest a moderately sound balance sheet relative to the weak operating picture.

For a prospective investor evaluating the stock today, the rating points to weak operating fundamentals (zero margins, zero ROIC, zero FCF yield) with only the balance-sheet pillar offering partial support. Upside would depend on a catalyst that the sources do not quantify; the rating itself frames the stock as a trim candidate rather than an accumulation candidate. This is an analytical summary, not personalized advice.

Per the recent news and catalysts feed, six items were published on the coverage window, all tagged to CRDL and all rated YELLOW light with a MARKET WIRE impact label:

• Stock-move coverage: Kalkine.ca reports on a down day tied to "Phase III Heart-Disease Data," a sentiment-pressure piece citing "Phase III Trial Transition and Cash Burn," and a follow-up on an up move noting investor attention.
• Management commentary: An ABN Newswire piece features CEO David Elsley discussing the "Phase III MAVERIC" program and next steps for CardiolRx.
• Positioning data: A MarketBeat short-interest and short-float update (Oct 2026).
• Price action: A Kalkine.ca item citing a +1.06% move on 7 October 2026.

Risk watch items per the feed: Phase III trial progress, cash burn, and short-interest positioning. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals (see below).

Per the Butterfly Supply-Chain Graph, the supply chain is "NONE," with an empty set of butterfly links and no proprietary signals. Sector is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances). Because no upstream or downstream dependencies are mapped, no second-order bottlenecks or sector-correlation effects can be stated from the source data. Investors should note that the absence of mapped links is itself a data gap, not evidence of independence.

• What are the revenue, operating income, net income, and cash/debt figures for any reported period? (Financials section is empty.)
• What are the P/E, EPS, and EV/EBITDA valuation metrics, which are currently unavailable?
• What is the status and timing of the Phase III MAVERIC program, and what is the cash runway implied by current burn?
• What analyst consensus rating or price targets exist, and what are current institutional and insider holdings?
• What supply-chain or sector-linked dependencies exist, given the graph is empty?